- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The Community-acquired Bacterial Pneumonia market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Community-acquired Bacterial Pneumonia size is estimated to be USD million in 2026 from USD million in 2020, with a change % between 2020 and 2021. The global Community-acquired Bacterial Pneumonia market size is expected to grow at a CAGR of % for the next five years.
Market segmentation
Community-acquired Bacterial Pneumonia market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Pleuromutilin Antibiotic
Cephalosporin
Glycylcycline
Oxazolidinone
Ketolide
Others
Market segment by Application, can be divided into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Market segment by players, this report covers
Nabriva Therapeutics
Paratek Pharmaceuticals
Melinta Therapeutics
Allergan plc
Bayer AG
Lupin Pharmaceuticals
Mylan N.V.
Sanofi S.A.
Pfizer Inc.
Dainippon Sumitomo Pharma
Takeda Pharmaceutical Company Limited
Basilea Pharmaceutica International AG
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Community-acquired Bacterial Pneumonia product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Community-acquired Bacterial Pneumonia, with revenue, gross margin and global market share of Community-acquired Bacterial Pneumonia from 2019 to 2021.
Chapter 3, the Community-acquired Bacterial Pneumonia competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Community-acquired Bacterial Pneumonia market forecast, by regions, type and distribution channel, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Community-acquired Bacterial Pneumonia research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Community-acquired Bacterial Pneumonia
1.2 Classification of Community-acquired Bacterial Pneumonia by Type
1.2.1 Overview: Global Community-acquired Bacterial Pneumonia Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type in 2020
1.2.3 Pleuromutilin Antibiotic
1.2.4 Cephalosporin
1.2.5 Glycylcycline
1.2.6 Oxazolidinone
1.2.7 Ketolide
1.2.8 Others
1.3 Global Community-acquired Bacterial Pneumonia Market by Distribution Channel
1.3.1 Overview: Global Community-acquired Bacterial Pneumonia Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Community-acquired Bacterial Pneumonia Market Size & Forecast
1.5 Global Community-acquired Bacterial Pneumonia Market Size and Forecast by Region
1.5.1 Global Community-acquired Bacterial Pneumonia Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Community-acquired Bacterial Pneumonia Market Size by Region, (2016-2021)
1.5.3 North America Community-acquired Bacterial Pneumonia Market Size and Prospect (2016-2026)
1.5.4 Europe Community-acquired Bacterial Pneumonia Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size and Prospect (2016-2026)
1.5.6 South America Community-acquired Bacterial Pneumonia Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Community-acquired Bacterial Pneumonia Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Community-acquired Bacterial Pneumonia Market Drivers
1.6.2 Community-acquired Bacterial Pneumonia Market Restraints
1.6.3 Community-acquired Bacterial Pneumonia Trends Analysis
2 Company Profiles
2.1 Nabriva Therapeutics
2.1.1 Nabriva Therapeutics Details
2.1.2 Nabriva Therapeutics Major Business
2.1.3 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product and Solutions
2.1.4 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Nabriva Therapeutics Recent Developments and Future Plans
2.2 Paratek Pharmaceuticals
2.2.1 Paratek Pharmaceuticals Details
2.2.2 Paratek Pharmaceuticals Major Business
2.2.3 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Solutions
2.2.4 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Paratek Pharmaceuticals Recent Developments and Future Plans
2.3 Melinta Therapeutics
2.3.1 Melinta Therapeutics Details
2.3.2 Melinta Therapeutics Major Business
2.3.3 Melinta Therapeutics Community-acquired Bacterial Pneumonia Product and Solutions
2.3.4 Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Melinta Therapeutics Recent Developments and Future Plans
2.4 Allergan plc
2.4.1 Allergan plc Details
2.4.2 Allergan plc Major Business
2.4.3 Allergan plc Community-acquired Bacterial Pneumonia Product and Solutions
2.4.4 Allergan plc Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Allergan plc Recent Developments and Future Plans
2.5 Bayer AG
2.5.1 Bayer AG Details
2.5.2 Bayer AG Major Business
2.5.3 Bayer AG Community-acquired Bacterial Pneumonia Product and Solutions
2.5.4 Bayer AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Bayer AG Recent Developments and Future Plans
2.6 Lupin Pharmaceuticals
2.6.1 Lupin Pharmaceuticals Details
2.6.2 Lupin Pharmaceuticals Major Business
2.6.3 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Solutions
2.6.4 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Lupin Pharmaceuticals Recent Developments and Future Plans
2.7 Mylan N.V.
2.7.1 Mylan N.V. Details
2.7.2 Mylan N.V. Major Business
2.7.3 Mylan N.V. Community-acquired Bacterial Pneumonia Product and Solutions
2.7.4 Mylan N.V. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Mylan N.V. Recent Developments and Future Plans
2.8 Sanofi S.A.
2.8.1 Sanofi S.A. Details
2.8.2 Sanofi S.A. Major Business
2.8.3 Sanofi S.A. Community-acquired Bacterial Pneumonia Product and Solutions
2.8.4 Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Sanofi S.A. Recent Developments and Future Plans
2.9 Pfizer Inc.
2.9.1 Pfizer Inc. Details
2.9.2 Pfizer Inc. Major Business
2.9.3 Pfizer Inc. Community-acquired Bacterial Pneumonia Product and Solutions
2.9.4 Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Pfizer Inc. Recent Developments and Future Plans
2.10 Dainippon Sumitomo Pharma
2.10.1 Dainippon Sumitomo Pharma Details
2.10.2 Dainippon Sumitomo Pharma Major Business
2.10.3 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product and Solutions
2.10.4 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Dainippon Sumitomo Pharma Recent Developments and Future Plans
2.11 Takeda Pharmaceutical Company Limited
2.11.1 Takeda Pharmaceutical Company Limited Details
2.11.2 Takeda Pharmaceutical Company Limited Major Business
2.11.3 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product and Solutions
2.11.4 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
2.12 Basilea Pharmaceutica International AG
2.12.1 Basilea Pharmaceutica International AG Details
2.12.2 Basilea Pharmaceutica International AG Major Business
2.12.3 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product and Solutions
2.12.4 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Basilea Pharmaceutica International AG Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Community-acquired Bacterial Pneumonia Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Community-acquired Bacterial Pneumonia Players Market Share
3.2.2 Top 10 Community-acquired Bacterial Pneumonia Players Market Share
3.2.3 Market Competition Trend
3.3 Community-acquired Bacterial Pneumonia Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Community-acquired Bacterial Pneumonia Revenue and Market Share by Type (2016-2021)
4.2 Global Community-acquired Bacterial Pneumonia Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2016-2021)
5.2 Community-acquired Bacterial Pneumonia Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Community-acquired Bacterial Pneumonia Revenue by Type (2016-2026)
6.2 North America Community-acquired Bacterial Pneumonia Revenue by Application (2016-2026)
6.3 North America Community-acquired Bacterial Pneumonia Market Size by Country
6.3.1 North America Community-acquired Bacterial Pneumonia Revenue by Country (2016-2026)
6.3.2 United States Community-acquired Bacterial Pneumonia Market Size and Forecast (2016-2026)
6.3.3 Canada Community-acquired Bacterial Pneumonia Market Size and Forecast (2016-2026)
6.3.4 Mexico Community-acquired Bacterial Pneumonia Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Community-acquired Bacterial Pneumonia Revenue by Type (2016-2026)
7.2 Europe Community-acquired Bacterial Pneumonia Revenue by Application (2016-2026)
7.3 Europe Community-acquired Bacterial Pneumonia Market Size by Country
7.3.1 Europe Community-acquired Bacterial Pneumonia Revenue by Country (2016-2026)
7.3.2 Germany Community-acquired Bacterial Pneumonia Market Size and Forecast (2016-2026)
7.3.3 France Community-acquired Bacterial Pneumonia Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Community-acquired Bacterial Pneumonia Market Size and Forecast (2016-2026)
7.3.5 Russia Community-acquired Bacterial Pneumonia Market Size and Forecast (2016-2026)
7.3.6 Italy Community-acquired Bacterial Pneumonia Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Community-acquired Bacterial Pneumonia Revenue by Type (2016-2026)
8.2 Asia-Pacific Community-acquired Bacterial Pneumonia Revenue by Application (2016-2026)
8.3 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region
8.3.1 Asia-Pacific Community-acquired Bacterial Pneumonia Revenue by Region (2016-2026)
8.3.2 China Community-acquired Bacterial Pneumonia Market Size and Forecast (2016-2026)
8.3.3 Japan Community-acquired Bacterial Pneumonia Market Size and Forecast (2016-2026)
8.3.4 South Korea Community-acquired Bacterial Pneumonia Market Size and Forecast (2016-2026)
8.3.5 India Community-acquired Bacterial Pneumonia Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Community-acquired Bacterial Pneumonia Market Size and Forecast (2016-2026)
8.3.7 Australia Community-acquired Bacterial Pneumonia Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Community-acquired Bacterial Pneumonia Revenue by Type (2016-2026)
9.2 South America Community-acquired Bacterial Pneumonia Revenue by Application (2016-2026)
9.3 South America Community-acquired Bacterial Pneumonia Market Size by Country
9.3.1 South America Community-acquired Bacterial Pneumonia Revenue by Country (2016-2026)
9.3.2 Brazil Community-acquired Bacterial Pneumonia Market Size and Forecast (2016-2026)
9.3.3 Argentina Community-acquired Bacterial Pneumonia Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Community-acquired Bacterial Pneumonia Revenue by Type (2016-2026)
10.2 Middle East & Africa Community-acquired Bacterial Pneumonia Revenue by Application (2016-2026)
10.3 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country
10.3.1 Middle East & Africa Community-acquired Bacterial Pneumonia Revenue by Country (2016-2026)
10.3.2 Turkey Community-acquired Bacterial Pneumonia Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Community-acquired Bacterial Pneumonia Market Size and Forecast (2016-2026)
10.3.4 UAE Community-acquired Bacterial Pneumonia Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Community-acquired Bacterial Pneumonia Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Community-acquired Bacterial Pneumonia Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Community-acquired Bacterial Pneumonia Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Community-acquired Bacterial Pneumonia Revenue (USD Million) by Region (2016-2021)
Table 5. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Region (2021-2026)
Table 6. Nabriva Therapeutics Corporate Information, Head Office, and Major Competitors
Table 7. Nabriva Therapeutics Major Business
Table 8. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product and Solutions
Table 9. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Paratek Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 11. Paratek Pharmaceuticals Major Business
Table 12. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Solutions
Table 13. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Melinta Therapeutics Corporate Information, Head Office, and Major Competitors
Table 15. Melinta Therapeutics Major Business
Table 16. Melinta Therapeutics Community-acquired Bacterial Pneumonia Product and Solutions
Table 17. Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Allergan plc Corporate Information, Head Office, and Major Competitors
Table 19. Allergan plc Major Business
Table 20. Allergan plc Community-acquired Bacterial Pneumonia Product and Solutions
Table 21. Allergan plc Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Bayer AG Corporate Information, Head Office, and Major Competitors
Table 23. Bayer AG Major Business
Table 24. Bayer AG Community-acquired Bacterial Pneumonia Product and Solutions
Table 25. Bayer AG Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Lupin Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 27. Lupin Pharmaceuticals Major Business
Table 28. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product and Solutions
Table 29. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Mylan N.V. Corporate Information, Head Office, and Major Competitors
Table 31. Mylan N.V. Major Business
Table 32. Mylan N.V. Community-acquired Bacterial Pneumonia Product and Solutions
Table 33. Mylan N.V. Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Sanofi S.A. Corporate Information, Head Office, and Major Competitors
Table 35. Sanofi S.A. Major Business
Table 36. Sanofi S.A. Community-acquired Bacterial Pneumonia Product and Solutions
Table 37. Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Pfizer Inc. Corporate Information, Head Office, and Major Competitors
Table 39. Pfizer Inc. Major Business
Table 40. Pfizer Inc. Community-acquired Bacterial Pneumonia Product and Solutions
Table 41. Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Dainippon Sumitomo Pharma Corporate Information, Head Office, and Major Competitors
Table 43. Dainippon Sumitomo Pharma Major Business
Table 44. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product and Solutions
Table 45. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Takeda Pharmaceutical Company Limited Corporate Information, Head Office, and Major Competitors
Table 47. Takeda Pharmaceutical Company Limited Major Business
Table 48. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product and Solutions
Table 49. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Basilea Pharmaceutica International AG Corporate Information, Head Office, and Major Competitors
Table 51. Basilea Pharmaceutica International AG Major Business
Table 52. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product and Solutions
Table 53. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Global Community-acquired Bacterial Pneumonia Revenue (USD Million) by Players (2019-2021)
Table 55. Global Community-acquired Bacterial Pneumonia Revenue Share by Players (2019-2021)
Table 56. Breakdown of Community-acquired Bacterial Pneumonia by Company Type (Tier 1, Tier 2 and Tier 3)
Table 57. Community-acquired Bacterial Pneumonia Players Head Office, Products and Services Provided
Table 58. Community-acquired Bacterial Pneumonia Mergers & Acquisitions in the Past Five Years
Table 59. Community-acquired Bacterial Pneumonia New Entrants and Expansion Plans
Table 60. Global Community-acquired Bacterial Pneumonia Revenue (USD Million) by Type (2016-2021)
Table 61. Global Community-acquired Bacterial Pneumonia Revenue Share by Type (2016-2021)
Table 62. Global Community-acquired Bacterial Pneumonia Revenue Forecast by Type (2021-2026)
Table 63. Global Community-acquired Bacterial Pneumonia Revenue by Application (2016-2021)
Table 64. Global Community-acquired Bacterial Pneumonia Revenue Forecast by Application (2021-2026)
Table 65. North America Community-acquired Bacterial Pneumonia Revenue by Type (2016-2021) & (USD Million)
Table 66. North America Community-acquired Bacterial Pneumonia Revenue by Type (2021-2026) & (USD Million)
Table 67. North America Community-acquired Bacterial Pneumonia Revenue by Application (2016-2021) & (USD Million)
Table 68. North America Community-acquired Bacterial Pneumonia Revenue by Application (2021-2026) & (USD Million)
Table 69. North America Community-acquired Bacterial Pneumonia Revenue by Country (2016-2021) & (USD Million)
Table 70. North America Community-acquired Bacterial Pneumonia Revenue by Country (2021-2026) & (USD Million)
Table 71. Europe Community-acquired Bacterial Pneumonia Revenue by Type (2016-2021) & (USD Million)
Table 72. Europe Community-acquired Bacterial Pneumonia Revenue by Type (2021-2026) & (USD Million)
Table 73. Europe Community-acquired Bacterial Pneumonia Revenue by Application (2016-2021) & (USD Million)
Table 74. Europe Community-acquired Bacterial Pneumonia Revenue by Application (2021-2026) & (USD Million)
Table 75. Europe Community-acquired Bacterial Pneumonia Revenue by Country (2016-2021) & (USD Million)
Table 76. Europe Community-acquired Bacterial Pneumonia Revenue by Country (2021-2026) & (USD Million)
Table 77. Asia-Pacific Community-acquired Bacterial Pneumonia Revenue by Type (2016-2021) & (USD Million)
Table 78. Asia-Pacific Community-acquired Bacterial Pneumonia Revenue by Type (2021-2026) & (USD Million)
Table 79. Asia-Pacific Community-acquired Bacterial Pneumonia Revenue by Application (2016-2021) & (USD Million)
Table 80. Asia-Pacific Community-acquired Bacterial Pneumonia Revenue by Application (2021-2026) & (USD Million)
Table 81. Asia-Pacific Community-acquired Bacterial Pneumonia Revenue by Region (2016-2021) & (USD Million)
Table 82. Asia-Pacific Community-acquired Bacterial Pneumonia Revenue by Region (2021-2026) & (USD Million)
Table 83. South America Community-acquired Bacterial Pneumonia Revenue by Type (2016-2021) & (USD Million)
Table 84. South America Community-acquired Bacterial Pneumonia Revenue by Type (2021-2026) & (USD Million)
Table 85. South America Community-acquired Bacterial Pneumonia Revenue by Application (2016-2021) & (USD Million)
Table 86. South America Community-acquired Bacterial Pneumonia Revenue by Application (2021-2026) & (USD Million)
Table 87. South America Community-acquired Bacterial Pneumonia Revenue by Country (2016-2021) & (USD Million)
Table 88. South America Community-acquired Bacterial Pneumonia Revenue by Country (2021-2026) & (USD Million)
Table 89. Middle East & Africa Community-acquired Bacterial Pneumonia Revenue by Type (2016-2021) & (USD Million)
Table 90. Middle East & Africa Community-acquired Bacterial Pneumonia Revenue by Type (2021-2026) & (USD Million)
Table 91. Middle East & Africa Community-acquired Bacterial Pneumonia Revenue by Application (2016-2021) & (USD Million)
Table 92. Middle East & Africa Community-acquired Bacterial Pneumonia Revenue by Application (2021-2026) & (USD Million)
Table 93. Middle East & Africa Community-acquired Bacterial Pneumonia Revenue by Country (2016-2021) & (USD Million)
Table 94. Middle East & Africa Community-acquired Bacterial Pneumonia Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Community-acquired Bacterial Pneumonia Picture
Figure 2. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type in 2020
Figure 3. Pleuromutilin Antibiotic
Figure 4. Cephalosporin
Figure 5. Glycylcycline
Figure 6. Oxazolidinone
Figure 7. Ketolide
Figure 8. Others
Figure 9. Community-acquired Bacterial Pneumonia Revenue Market Share by Distribution Channel in 2020
Figure 10. Hospital Pharmacies Picture
Figure 11. Retail Pharmacies Picture
Figure 12. Online Pharmacies Picture
Figure 13. Global Community-acquired Bacterial Pneumonia Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 14. Global Community-acquired Bacterial Pneumonia Revenue and Forecast (2016-2026) & (USD Million)
Figure 15. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Region (2016-2026)
Figure 16. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Region in 2020
Figure 17. North America Community-acquired Bacterial Pneumonia Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Europe Community-acquired Bacterial Pneumonia Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Asia-Pacific Community-acquired Bacterial Pneumonia Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. South America Community-acquired Bacterial Pneumonia Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Middle East and Africa Community-acquired Bacterial Pneumonia Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. Community-acquired Bacterial Pneumonia Market Drivers
Figure 23. Community-acquired Bacterial Pneumonia Market Restraints
Figure 24. Community-acquired Bacterial Pneumonia Market Trends
Figure 25. Nabriva Therapeutics Recent Developments and Future Plans
Figure 26. Paratek Pharmaceuticals Recent Developments and Future Plans
Figure 27. Melinta Therapeutics Recent Developments and Future Plans
Figure 28. Allergan plc Recent Developments and Future Plans
Figure 29. Bayer AG Recent Developments and Future Plans
Figure 30. Lupin Pharmaceuticals Recent Developments and Future Plans
Figure 31. Mylan N.V. Recent Developments and Future Plans
Figure 32. Sanofi S.A. Recent Developments and Future Plans
Figure 33. Pfizer Inc. Recent Developments and Future Plans
Figure 34. Dainippon Sumitomo Pharma Recent Developments and Future Plans
Figure 35. Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
Figure 36. Basilea Pharmaceutica International AG Recent Developments and Future Plans
Figure 37. Global Community-acquired Bacterial Pneumonia Revenue Share by Players in 2020
Figure 38. Community-acquired Bacterial Pneumonia Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 39. Global Top 3 Players Community-acquired Bacterial Pneumonia Revenue Market Share in 2020
Figure 40. Global Top 10 Players Community-acquired Bacterial Pneumonia Revenue Market Share in 2020
Figure 41. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 42. Global Community-acquired Bacterial Pneumonia Revenue Share by Type in 2020
Figure 43. Global Community-acquired Bacterial Pneumonia Market Share Forecast by Type (2021-2026)
Figure 44. Global Community-acquired Bacterial Pneumonia Revenue Share by Application in 2020
Figure 45. Global Community-acquired Bacterial Pneumonia Market Share Forecast by Application (2021-2026)
Figure 46. North America Community-acquired Bacterial Pneumonia Sales Market Share by Type (2016-2026)
Figure 47. North America Community-acquired Bacterial Pneumonia Sales Market Share by Application (2016-2026)
Figure 48. North America Community-acquired Bacterial Pneumonia Revenue Market Share by Country (2016-2026)
Figure 49. United States Community-acquired Bacterial Pneumonia Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Canada Community-acquired Bacterial Pneumonia Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Mexico Community-acquired Bacterial Pneumonia Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Europe Community-acquired Bacterial Pneumonia Sales Market Share by Type (2016-2026)
Figure 53. Europe Community-acquired Bacterial Pneumonia Sales Market Share by Application (2016-2026)
Figure 54. Europe Community-acquired Bacterial Pneumonia Revenue Market Share by Country (2016-2026)
Figure 55. Germany Community-acquired Bacterial Pneumonia Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. France Community-acquired Bacterial Pneumonia Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. United Kingdom Community-acquired Bacterial Pneumonia Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Russia Community-acquired Bacterial Pneumonia Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Italy Community-acquired Bacterial Pneumonia Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Asia-Pacific Community-acquired Bacterial Pneumonia Sales Market Share by Type (2016-2026)
Figure 61. Asia-Pacific Community-acquired Bacterial Pneumonia Sales Market Share by Application (2016-2026)
Figure 62. Asia-Pacific Community-acquired Bacterial Pneumonia Revenue Market Share by Region (2016-2026)
Figure 63. China Community-acquired Bacterial Pneumonia Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Japan Community-acquired Bacterial Pneumonia Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South Korea Community-acquired Bacterial Pneumonia Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. India Community-acquired Bacterial Pneumonia Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Southeast Asia Community-acquired Bacterial Pneumonia Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Australia Community-acquired Bacterial Pneumonia Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. South America Community-acquired Bacterial Pneumonia Sales Market Share by Type (2016-2026)
Figure 70. South America Community-acquired Bacterial Pneumonia Sales Market Share by Application (2016-2026)
Figure 71. South America Community-acquired Bacterial Pneumonia Revenue Market Share by Country (2016-2026)
Figure 72. Brazil Community-acquired Bacterial Pneumonia Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Argentina Community-acquired Bacterial Pneumonia Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Middle East and Africa Community-acquired Bacterial Pneumonia Sales Market Share by Type (2016-2026)
Figure 75. Middle East and Africa Community-acquired Bacterial Pneumonia Sales Market Share by Application (2016-2026)
Figure 76. Middle East and Africa Community-acquired Bacterial Pneumonia Revenue Market Share by Country (2016-2026)
Figure 77. Turkey Community-acquired Bacterial Pneumonia Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Saudi Arabia Community-acquired Bacterial Pneumonia Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. UAE Community-acquired Bacterial Pneumonia Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Methodology
Figure 81. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
